BT-600: Liquid formulation of tofacitinib delivered via the NaviCap platform for the treatment of ulcerative colitis
We are developing BT-600 (formerly PGN-600) as an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis. Tofacitinib is approved for ulcerative colitis and is dose limited based on safety concerns, making it an ideal therapy for targeted delivery.
Our preclinical data demonstrates that targeted delivery using BT-600 can lead to reduced drug levels in blood and to increased levels in tissue at least 25 times higher along the length of the colon versus the equivalent standard oral dose.
If we demonstrate similar results clinically to what has been observed preclinically, and given the known efficacy of the currently approved doses of tofacitinib, we believe BT-600 has the potential to greatly improve patient outcomes in ulcerative colitis.
BT-600 is currently in preclinical stage development.
BT-001: Liquid formulation of Anti-TNF-alpha monoclonal antibody delivered via the NaviCap platform for the treatment of ulcerative colitis
We are developing BT-001 (formerly PGN-001) as an orally-delivered variant of adalimumab for the treatment of ulcerative colitis (UC). Multiple anti-TNF-alpha targeting therapies have been approved for UC, but data suggests patients may not have enough drug in the tissue to engage the target, TNF-alpha, and reduce inflammation. We have developed our own anti-TNF-alpha antibody formulation for use in further development.
BT-001 is currently in preclinical stage development. We have conducted a series of preclinical studies demonstrating the potential of locally delivered anti-TNF-alpha antibodies to reduce disease burden in UC models.